PEGLAX ORANGE

Kraj: Izrael

Język: angielski

Źródło: Ministry of Health

Kup teraz

Składnik aktywny:

POLYETHYLENE GLYCOL 3350

Dostępny od:

NEOPHARM CONSUMER PRODUCTS LTD, ISRAEL

Kod ATC:

A06AD15

Forma farmaceutyczna:

POWDER FOR ORAL SOLUTION

Skład:

POLYETHYLENE GLYCOL 3350 99.365 %W/W

Droga podania:

PER OS

Typ recepty:

Not required

Wyprodukowano przez:

BEN SHIMON FLORIS LTD, ISRAEL

Dziedzina terapeutyczna:

MACROGOL

Wskazania:

Treatment of constipation.

Data autoryzacji:

2015-10-31

Ulotka dla pacjenta

                                PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS
(PREPARATIONS) – 1986
This medicine is dispensed without a doctor’s prescription
PEGLAX NEUTRAL
Powder for preparing an oral solution
THE ACTIVE INGREDIENT AND ITS CONCENTRATION:
Polyethylene glycol 3350, 99.973% w/w
INACTIVE INGREDIENTS:
see section 6 in the leaflet – “
ADDITIONAL INFORMATION
”.
PEGLAX ORANGE
Powder for preparing an oral solution
THE ACTIVE INGREDIENT AND ITS CONCENTRATION:
Polyethylene glycol 3350, 99.365% w/w
INACTIVE INGREDIENTS:
see section 6 in the leaflet – “
ADDITIONAL INFORMATION
”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE MEDICINE.
This leaflet contains concise
information about the medicine. If you have additional questions,
refer to the doctor or the
pharmacist.
Use the preparation according to the instructions in the dosage
section of this leaflet.
Consult the pharmacist if you need more information. Refer to the
doctor if signs of the
ailment (symptoms) worsen or do not improve.
Peglax does not contain sugar and is therefore suitable for diabetics.
1. WHAT IS THE MEDICINE INTENDED FOR?
The medicine is intended for treatment of constipation. Peglax softens
the stool by
increasing the stool water content, causes normal intestinal activity
and thus relieves
constipation.
THERAPEUTIC CLASS:
Osmotic laxative.
2. BEFORE USING THE MEDICINE
DO NOT USE THIS MEDICINE IF:
•
You are sensitive (allergic) to the active ingredient (polyethylene
glycol 3350) or
to any of the other ingredients this medicine contains (for a list of
inactive
ingredients see section 6 in leaflet – “Additional
information”).
•
You suffer from an intestinal or colon disease (such as ulcerative
inflammation of
the large intestine, Crohn’s disease).
•
You suffer from abdominal pain of undetermined cause.
•
You have or suspect you may have gastrointestinal perforation.
•
You have or suspect you may have bowel obstruction.
SPECIAL WARNINGS REGARDING THE USE OF THE MEDICINE
•
The medicine contains polyethylene glyco
                                
                                Przeczytaj cały dokument
                                
                            

Dokumenty w innych językach

Ulotka dla pacjenta Ulotka dla pacjenta arabski 13-12-2022
Ulotka dla pacjenta Ulotka dla pacjenta hebrajski 13-12-2022

Wyszukaj powiadomienia związane z tym produktem

Zobacz historię dokumentów